Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Praziquantel

FDA-approved product (tablet, oral), marketed as Biltricide, Praziquantel.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Praziquantel
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Helminthiasis
  • Infection
  • Opisthorchiasis
  • Schistosomiasis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Quinoline derivatives and related substances
FDA pharmacologic class
Anthelmintic FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC P02BA01; FDA class Anthelmintic

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA41.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli41.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae29.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis58.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Praziquantel in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Praziquantel with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Repeated Doses of Praziquantel in Schistosomiasis Treatment (RePST)

    NCT02868385 · start 2018-10-01

    Registered record
    Registry ID
    NCT02868385
    Conditions
    Schistosomiasis
    Interventions
    4x Praziquantel; 1x Praziquantel
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-10-01
    Completion
    2019-01-14
    Enrolment
    167

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchistosomiasis
    Intervention4x Praziquantel; 1x Praziquantel
    PhasePhase 3
    Registry statusCompleted

  • Praziquantel Bioequivalence Study

    NCT03437447 · start 2018-06-18

    Registered record
    Registry ID
    NCT03437447
    Conditions
    Healthy
    Interventions
    Cisticid; Biltricide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-06-18
    Completion
    2018-07-06
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionCisticid; Biltricide
    PhasePhase 1
    Registry statusCompleted

  • Relative Bioavailability Study of Emodepside IR-tablets and Solution

    NCT03383523 · start 2017-10-26

    Registered record
    Registry ID
    NCT03383523
    Conditions
    Filariasis
    Interventions
    Emodepside (BAY 44-4400)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-10-26
    Completion
    2018-03-26
    Enrolment
    77

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFilariasis
    InterventionEmodepside (BAY 44-4400)
    PhasePhase 1
    Registry statusCompleted

  • The Chinese-made Praziquantel for Treatment of Schistosoma Haematobium

    NCT03133832 · start 2017-04-10

    Registered record
    Registry ID
    NCT03133832
    Conditions
    Schistosomiasis Haematobia
    Interventions
    Companion Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2017-04-10
    Completion
    2017-07-10
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchistosomiasis Haematobia
    InterventionCompanion Tablet
    PhasePhase 3
    Registry statusUnknown

  • Study of Safety and Immune Response of the Sm14 Vaccine in Adults of Endemic Regions

    NCT03041766 · start 2016-12-06

    Registered record
    Registry ID
    NCT03041766
    Conditions
    Schistosomiasis
    Interventions
    Sm14; GLA-SE solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-12-06
    Completion
    2017-06-02
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchistosomiasis
    InterventionSm14; GLA-SE solution
    PhasePhase 2
    Registry statusCompleted

  • Sub Arachnoid Neurocysticercosis Treatment Outcome (SANTO)

    NCT02947581 · start 2016-11-14

    Registered record
    Registry ID
    NCT02947581
    Conditions
    Neurocysticercosis
    Interventions
    Albendazole and praziquantel; Albendazole and praziquantel placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2016-11-14
    Completion
    2021-02-27
    Enrolment
    107

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeurocysticercosis
    InterventionAlbendazole and praziquantel; Albendazole and praziquantel placebo
    PhasePhase 3
    Registry statusTerminated

  • Effect of Concomitant Mansonella Perstans Microfilaremia on Immune Responses Following Single Dose Praziquantel in People With Schistosomiasis

    NCT02734186 · start 2016-04-06

    Registered record
    Registry ID
    NCT02734186
    Conditions
    Schistosomiasis
    Interventions
    Praziquantel
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2016-04-06
    Completion
    2018-12-14
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchistosomiasis
    InterventionPraziquantel
    PhasePhase 4
    Registry statusWithdrawn

  • Assessing the Effect of Neglected Tropical Diseases on Plasmodium Falciparum Transmission in an Area of Co-endemicity

    NCT02769013 · start 2016-04

    Registered record
    Registry ID
    NCT02769013
    Conditions
    Malaria Transmission
    Interventions
    Pre-treatment follow up; S. haematobium treatment; Post treatment follow up; Olfactometer experiment
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2016-04
    Completion
    2020-10
    Enrolment
    380

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria Transmission
    InterventionPre-treatment follow up; S. haematobium treatment; Post treatment follow up; Olfactometer experiment
    PhaseNot recorded
    Registry statusCompleted

  • Taenia Solium Elimination Versus Control: What is the Best Way Forward for Sub-Saharan Africa?

    NCT02612896 · start 2016-03

    Registered record
    Registry ID
    NCT02612896
    Conditions
    Taenia Solium Infection
    Interventions
    Mass drug administration, praziquantel 10mg/kg; Health education
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2016-03
    Completion
    2022-02
    Enrolment
    2,900

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTaenia Solium Infection
    InterventionMass drug administration, praziquantel 10mg/kg; Health education
    PhaseNot applicable
    Registry statusCompleted

  • Cross-over Study to Evaluate the Palatability of New Orally Disintegrating Tablets (ODTs) of Praziquantel (PZQ) and L-PZQ Versus Current PZQ Tablets in African Children Age 6-11 Years

    NCT02315352 · start 2015-04

    Registered record
    Registry ID
    NCT02315352
    Conditions
    Healthy
    Interventions
    L-PZQ ODT; Rac-PZQ ODT; L-PZQ ODT; Rac-PZQ ODT; Cesol®
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-04
    Completion
    2015-05
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionL-PZQ ODT; Rac-PZQ ODT; L-PZQ ODT; Rac-PZQ ODT +1 more
    PhasePhase 1
    Registry statusCompleted

  • Relative Bioavailability Trial of Oral Dispersible Praziquantel Tablets in Healthy Volunteers

    NCT02325713 · start 2015-01

    Registered record
    Registry ID
    NCT02325713
    Conditions
    Healthy
    Interventions
    Oral dispersible tablet of praziquantel (ODT-PZQ); Cysticide; ODT-PZQ; ODT-PZQ; ODT-PZQ; Cysticide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-01
    Completion
    2015-03
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionOral dispersible tablet of praziquantel (ODT-PZQ); Cysticide; ODT-PZQ; ODT-PZQ +2 more
    PhasePhase 1
    Registry statusCompleted

  • Relative Bioavailability Trial of L-Praziquantel in Healthy Volunteers

    NCT02271984 · start 2014-10-31

    Registered record
    Registry ID
    NCT02271984
    Conditions
    Healthy
    Interventions
    MSC2499550A; Cysticide; MSC2499550A; MSC2499550A; MSC2499550A; MSC2499550A
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-10-31
    Completion
    2014-12-31
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionMSC2499550A; Cysticide; MSC2499550A; MSC2499550A +2 more
    PhasePhase 1
    Registry statusCompleted

  • Arachidonic Acid Treatment Against Schistosomiasis Infection in Children

    NCT02144389 · start 2013-01

    Registered record
    Registry ID
    NCT02144389
    Conditions
    Schistosomiasis; Bilharzia
    Interventions
    Praziquantel (PZQ); Arachidonic acid (ARA); PZQ+ARA
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2013-01
    Completion
    2014-01
    Enrolment
    335

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchistosomiasis; Bilharzia
    InterventionPraziquantel (PZQ); Arachidonic acid (ARA); PZQ+ARA
    PhaseNot applicable
    Registry statusCompleted

  • Schistosoma Mansoni Morbidity in Children Aged 1-5 Years

    NCT01901484 · start 2012-12

    Registered record
    Registry ID
    NCT01901484
    Conditions
    Intestinal Schistosomiasis
    Interventions
    Praziquantel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-12
    Completion
    2014-02
    Enrolment
    800

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIntestinal Schistosomiasis
    InterventionPraziquantel
    PhasePhase 2
    Registry statusCompleted

  • Impact IPT With Sulfadoxine-pyrimethamine or Sulfadoxine-pyrimethamine Plus Piperaquine in Schoolchildren

    NCT01722539 · start 2012-11

    Registered record
    Registry ID
    NCT01722539
    Conditions
    Healthy
    Interventions
    Sulfadoxine-pyrimethamine; Piperaquine; Albendazole; Praziquantel
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-11
    Completion
    2013-11
    Enrolment
    616

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionSulfadoxine-pyrimethamine; Piperaquine; Albendazole; Praziquantel
    PhasePhase 3
    Registry statusCompleted